Literature DB >> 12390543

Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge.

J D Lifson1, M Piatak, J L Rossio, J Bess, E Chertova, D Schneider, R Kiser, V Coalter, B Poore, R Imming, R C Desrosiers, L E Henderson, L O Arthur.   

Abstract

A novel type of whole inactivated simian immunodeficiency virus (SIV) virion vaccine immunogen with functional envelope glycoproteins was evaluated, without adjuvant, in rhesus macaques. Immunogens included purified inactivated virions of SIVmac239, a designed mutant of SIVmac239 with gp120 carbohydrate attachment sites deleted (SIVmac239 g4,5), and SIVmneE11S. The vaccines were noninfectious, safe, and immunogenic, inducing antibody responses and cellular responses, including responses by CD8+ lymphocytes. Interpretation of protective efficacy following intrarectal challenge was complicated by incomplete take of the challenge in some SIV naïve controls.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390543     DOI: 10.1034/j.1600-0684.2002.02007.x

Source DB:  PubMed          Journal:  J Med Primatol        ISSN: 0047-2565            Impact factor:   0.667


  16 in total

1.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

2.  Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression.

Authors:  Jonah B Sacha; Chungwon Chung; Eva G Rakasz; Sean P Spencer; Anna K Jonas; Alexander T Bean; Wonhee Lee; Benjamin J Burwitz; Jason J Stephany; John T Loffredo; David B Allison; Sama Adnan; Akihiko Hoji; Nancy A Wilson; Thomas C Friedrich; Jeffrey D Lifson; Otto O Yang; David I Watkins
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

Review 3.  Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets.

Authors:  S Phogat; R T Wyatt; G B Karlsson Hedestam
Journal:  J Intern Med       Date:  2007-07       Impact factor: 8.989

4.  Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Authors:  Yasushi Ami; Yasuyuki Izumi; Kazuhiro Matsuo; Kenji Someya; Masaru Kanekiyo; Shigeo Horibata; Naoto Yoshino; Koji Sakai; Katsuaki Shinohara; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

5.  Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins.

Authors:  David R Morcock; James A Thomas; Tracy D Gagliardi; Robert J Gorelick; J David Roser; Elena N Chertova; Julian W Bess; David E Ott; Quentin J Sattentau; Ines Frank; Melissa Pope; Jeffrey D Lifson; Louis E Henderson; Bruce J Crise
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

Review 6.  Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.

Authors:  Laurent Verkoczy; Frederick W Alt; Ming Tian
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

7.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

8.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Authors:  Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

10.  Noninfectious X4 but not R5 human immunodeficiency virus type 1 virions inhibit humoral immune responses in human lymphoid tissue ex vivo.

Authors:  Wendy Fitzgerald; Andrew W Sylwester; Jean-Charles Grivel; Jeffrey D Lifson; Leonid B Margolis
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.